Rutin Therapy Role in Reducing Ulcerative Colitis Severity
NCT ID: NCT07147842
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2024-11-01
2025-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A key player in the inflammation process is the NLRP3 inflammasome. This inflammasome's expression is heightened and activated by reactive oxygen species (ROS). Its activity is influenced by various factors, including the ubiquitin system, ion channels, and gut microbiota.
Rutin, a compound found in many fruits and vegetables, has been shown to have properties that help scavenge free radicals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rupatadine in Patients With Ulcerative Colitis
NCT07064707
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
NCT00694980
Oncostatin M in Ulcerative Colitis Patients
NCT05974332
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
NCT01336465
Pentoxifylline in Patients With Ulcerative Colitis
NCT07349472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ulcerative Colitis-A (UC-A)
Patients diagnosed with active Ulcerative Colitis were assigned as group UC-A
Rutin 500 MG
Rutin 500 mg capsules twice daily for 30 days
fecal calprotectin
Fecal calprotectin level was measured using an ELISA kit .
Ulcerative Colitis-B (UC-B)
Patients diagnosed with remission Ulcerative Colitis were assigned as control group UC-B
Placebo
Placebo Tablets
fecal calprotectin
Fecal calprotectin level was measured using an ELISA kit .
Healthy Group (C)
Healthy volunteers provided samples as negative controls; and was assigned as group C
fecal calprotectin
Fecal calprotectin level was measured using an ELISA kit .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rutin 500 MG
Rutin 500 mg capsules twice daily for 30 days
Placebo
Placebo Tablets
fecal calprotectin
Fecal calprotectin level was measured using an ELISA kit .
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with positive microscopic mucosal changes consistent with UC.
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Afnan El Gindy
Lecturer of Physiology, Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha University
Banhā, El Qalyoubia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC 3.7.2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.